<div id="readability-page-1"><p>Baxter International Inc. (NYSE:BAX - Get Free Report) hit a new 52-week low on Thursday after the company announced weaker than expected quarterly earnings. The company traded as low as $24.73 and last traded at $22.98, with a volume of 139193 shares. The stock had previously closed at $28.05.</p><ul><li>The Value Deepens for Medtech Stocks: Reversal Imminent</li></ul><p>The medical instruments supplier reported $0.59 earnings per share for the quarter, missing analysts' consensus estimates of $0.60 by ($0.01). Baxter International had a negative net margin of 4.71% and a positive return on equity of 17.24%. Baxter International's revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.68 EPS. </p><div><p><span></span><span>Get <strong>Baxter International</strong> alerts:</span></p></div><h2>Baxter International Dividend Announcement</h2><p>The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 1st. Stockholders of record on Friday, August 29th will be paid a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a dividend yield of 2.90%. The ex-dividend date is Friday, August 29th. Baxter International's dividend payout ratio  is presently -61.82%. </p><h2>Wall Street Analysts Forecast Growth</h2><ul><li>A Significant Reversal is in Sight for These 5 Med Tech Companies</li></ul><p>Several equities analysts have recently commented on BAX shares. Citigroup decreased their price target on Baxter International from $34.00 to $32.00 and set a &#34;neutral&#34; rating on the stock in a research note on Wednesday, July 9th. Morgan Stanley cut their price target on Baxter International from $28.00 to $27.00 and set an &#34;underweight&#34; rating on the stock in a report on Tuesday, July 15th. Wall Street Zen upgraded Baxter International from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Sunday, June 22nd. Wells Fargo &amp; Company dropped their price target on Baxter International from $36.00 to $33.00 and set an &#34;equal weight&#34; rating on the stock in a research note on Friday, May 2nd. Finally, Evercore ISI decreased their price objective on Baxter International from $44.00 to $42.00 and set an &#34;outperform&#34; rating for the company in a research report on Tuesday, July 8th. One research analyst  has rated the stock with a sell rating, three have issued  a hold rating and six have issued  a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $36.38.</p><p><b>Check Out Our Latest Report on Baxter International</b></p><h2>Hedge Funds Weigh In On Baxter International</h2><ul><li>5 Good Reasons it's Time to Buy High-Yield Dividend King 3M</li></ul><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in BAX. Allstate Corp bought a new position in  Baxter International during the 4th quarter valued at $450,000.  Geode Capital Management LLC lifted its holdings in shares of  Baxter International by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 12,446,939 shares of the medical instruments supplier's stock valued at $362,006,000 after purchasing an additional 290,279 shares in the last quarter.  Oarsman Capital Inc. purchased a new stake in shares of  Baxter International in the fourth quarter valued at $157,000.  Russell Investments Group Ltd. lifted its holdings in shares of  Baxter International by 40.4% in the fourth quarter. Russell Investments Group Ltd. now owns 1,745,709 shares of the medical instruments supplier's stock valued at $50,904,000 after purchasing an additional 502,370 shares in the last quarter.  Finally, Jaffetilchin Investment Partners LLC raised its holdings in shares of  Baxter International by 115,259.6% during the fourth quarter. Jaffetilchin Investment Partners LLC now owns 65,755 shares of the medical instruments supplier's stock worth $1,917,000 after acquiring an additional 65,698 shares in the last quarter. 90.19% of the stock is owned by institutional investors. </p><h2>Baxter International Trading Down 16.4%</h2><p>The company has a fifty day simple moving average of $29.86 and a two-hundred day simple moving average of $31.14. The company has a debt-to-equity ratio of 1.33, a current ratio of 2.02 and a quick ratio of 1.40. The company has a market capitalization of $12.03 billion, a P/E ratio of -21.07, a price-to-earnings-growth ratio of 0.85 and a beta of 0.61. </p><h2>About Baxter International</h2> (Get Free Report)<p>Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Baxter International</li><li>5 discounted opportunities for dividend growth investors</li><li>Higher Consumer Confidence Could Benefit These 3 Retail Stocks</li><li>How to Profit From Value Investing </li><li>2 Cybersecurity Giants Nearing Big Potential Breakouts</li><li>What Are Dividend Champions? How to Invest in the Champions</li><li>Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Baxter International Right Now?</h2><p>Before you consider Baxter International, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Baxter International wasn't on the list.</p><p>While Baxter International currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Baxter International (NYSE:BAX) reached a new 52-week low of $22.98 following disappointing quarterly earnings, missing analysts' expectations with $0.59 EPS. The company's revenue increased by 4.3% year-over-year, but it reported a negative net margin of 4.71%. Baxter also declared a quarterly dividend of $0.17, with a yield of 2.90%. Analysts have mixed ratings on the stock, with an average target price of $36.38. Institutional investors hold 90.19% of the shares, and the stock has dropped 16.4% recently.</p>

Baxter International (NYSE:BAX) Hits New 52-Week Low on Disappointing Earnings